for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novacyt SA

NCYT.L

Latest Trade

287.50GBp

Change

-17.50(-5.74%)

Volume

824,391

Today's Range

286.20

 - 

308.00

52 Week Range

6.03

 - 

529.00

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
305.00
Open
305.00
Volume
824,391
3M AVG Volume
47.62
Today's High
308.00
Today's Low
286.20
52 Week High
529.00
52 Week Low
6.03
Shares Out (MIL)
58.09
Market Cap (MIL)
229.18
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Novacyt To Launch More COVID-19 Testing Products

Novacyt Contributes To Clinical Trial With Near-Patient Testing System

Novacyt SA Estimates EBITDA Profitability Over EUR45 Mln For HY

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novacyt SA

Novacyt SA is a France-based company that develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The Company develops a secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The Company creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of over 10 distributors.

Industry

Medical Equipment & Supplies

Contact Info

13 avenue Morane Saulnier

78140

France

+33.1.39465104

https://novacyt.com/

Executive Leadership

James Christopher Wakefield

Independent Non-Executive Chairman

Graham D. Mullis

Chief Executive Officer, Executive Director, Member of the Executive Team

Anthony William Dyer

Chief Financial Officer, Executive Director, Company Secretary, Member of the Executive Team

Wendy Karban

Member of the Executive Team, Group Human Resource Manager

Mandy Cowling

Member of the Executive Team, Corporate & Investor Relations Manager

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
17.52
Price To Book (MRQ)
12.92
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
74.76
LT Debt To Equity (MRQ)
58.20
Return on Investment (TTM)
-16.94
Return on Equity (TTM)
-12.27

Latest News

Latest News

Diagnostics group Novacyt to launch more COVID-19 testing products

Clinical diagnostics company Novacyt <ALNOV.PA> <NCYT.L> - one of many healthcare companies whose shares have surged during the pandemic - announced on Monday more new products to test for the presence of the coronavirus.

London stocks slip as BoE slows bond purchases; AstraZeneca weighs

UK shares fell on Thursday after the Bank of England's slowed the pace of its huge bond-buying programme, while a surge in coronavirus cases in the United States and China fanned fears of a second wave of infections.

Novacyt shares jump after launch of new COVID-19 testing products

Healthcare and clinical diagnostics company Novacyt <ALNOV.PA> <NCYT.L>, whose shares have surged on the back of its COVID-19 testing products, on Thursday announced the launch of three new products to support testing for the presence of the virus.

BRIEF-Novacyt Launches Three Products For COVID-19

* NOVACYT S.A.: LAUNCH OF THREE INNOVATIVE PRODUCTS TO SUPPORT COVID-19 TESTING

Novacyt launches three new products to support COVID-19 testing

Healthcare and clinical diagnostics company Novacyt , whose shares have surged on the back of its COVID-19 testing products, announced on Thursday the launch of three new products to support testing for the presence of the virus.

BRIEF-Novacyt: to settle debts with Harbert European Growth Capital and Vatel

* NOVACYT S.A.: EARLY SETTLEMENT OF TERM LOAN AND CONVERTIBLE BOND FACILITY REMOVES LONG TERM DEBT

Novacyt shares drop as France refuses to refund virus test

High-flying shares in Novacyt <ALNOV.PA> <NCYT.L> dropped as much as 12% on Tuesday after the healthcare diagnostics firm said a French regulator had decided against approving the company's coronavirus test for reimbursement by the state.

BRIEF-Novacyt Sees More COVID-19 Related Sales In H2

* AS OF 1 JUNE 2020, SALES OF PRIMERDESIGN COVID-19 TEST ARE EUR 45 MILLION (£40 MILLION)

Novacyt sees more wins for coronavirus test product

Healthcare and clinical diagnostics company Novacyt announced more contract wins for its 'Primerdesign' product aimed at testing for the presence of the coronavirus, although the company suffered a minor setback in France.

BRIEF-Novacyt FY Net Loss Widens To 6.6 Million Euros

* FY NET LOSS -6.6 MILLION EUR VERSUS -4.7 MILLION EUR LOSS YEAR AGO

BRIEF-Novacyt Contracted To Deliver Over 103 Million Euros Of COVID-19 Test

* AS OF 28 APRIL 2020, PRIMERDESIGN HAS SOLD, RECEIVED ORDERS FOR OR HAS BEEN CONTRACTED TO DELIVER OVER £90 MILLION (EUR 103 MILLION) OF ITS COVID-19 TEST

Novacyt signs coronavirus test supply contract with UK government

Healthcare and clinical diagnostics company Novacyt has signed a supply contract with the UK's Department of Health & Social Care (DHSC) for its product aimed at testing for the presence of the coronavirus, the company said on Monday.

UK shares climb on hopes of lockdown easing, Novacyt soars

London-listed shares joined a global rally on Monday as signs of an easing in the coronavirus outbreak raised hopes that a month-long lockdown would be relaxed, while diagnostics firm Novacyt surged on news of a supply contract with the UK government.

BRIEF-Novacyt S.A. Says Signed Manufacturing Partnership Agreements For Its Covid-19 Test

* NOVACYT S.A. - MANUFACTURING AND RESEARCH AND DEVELOPMENT UPDATE FOR COVID-19 TEST

BRIEF-Novacyt's COVID-19 Test Eligible For WHO Emergency Use Listing

* NOVACYT COVID-19 TEST ELIGIBLE FOR WHO EMERGENCY USE LISTING

BRIEF-Novacyt Partners With AstraZeneca, GSK, University Of Cambridge To Increase COVID-19 Testing

* COLLABORATION WITH ASTRAZENECA, GSK AND UNIVERSITY OF CAMBRIDGE TO SUPPORT UK NATIONAL EFFORT TO INCREASE COVID-19 TESTING Source text for Eikon: Further company coverage: (Gdansk Newsroom)

UK shares rises as coronavirus-related deaths slow

UK shares gained on Monday as investors cheered signs of slowing coronavirus-related deaths in the hotspots of western Europe.

Novacyt wins French approval for COVID testing kit

Novacyt's COVID-19 diagnostic test has been approved by France's CNR arm of the Institut Pasteur, making it available for immediate distribution in France, the healthcare company said on Monday.

UPDATE 1-Novacyt wins French approval for COVID testing kit

Novacyt's COVID-19 diagnostic test has been approved by France's CNR arm of the Institut Pasteur, making it available for immediate distribution in France, the healthcare company said on Monday.

BRIEF-CNR Of Institut Pasteur Has Approved COVID-19 Test Of Novacyt

* CNR (CENTRE NATIONAL DE RÉFÉRENCE DES VIRUS DES INFECTIONS RESPIRATOIRES (DONT LA GRIPPE)) OF INSTITUT PASTEUR, HAS APPROVED ITS COVID-19 TEST

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up